1. Home
  2. CTNM vs LOCO Comparison

CTNM vs LOCO Comparison

Compare CTNM & LOCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • LOCO
  • Stock Information
  • Founded
  • CTNM 2009
  • LOCO 1980
  • Country
  • CTNM United States
  • LOCO United States
  • Employees
  • CTNM N/A
  • LOCO N/A
  • Industry
  • CTNM
  • LOCO Restaurants
  • Sector
  • CTNM
  • LOCO Consumer Discretionary
  • Exchange
  • CTNM Nasdaq
  • LOCO Nasdaq
  • Market Cap
  • CTNM 377.6M
  • LOCO 412.4M
  • IPO Year
  • CTNM 2024
  • LOCO 2014
  • Fundamental
  • Price
  • CTNM $11.28
  • LOCO $11.52
  • Analyst Decision
  • CTNM Strong Buy
  • LOCO Hold
  • Analyst Count
  • CTNM 4
  • LOCO 2
  • Target Price
  • CTNM $29.25
  • LOCO $13.00
  • AVG Volume (30 Days)
  • CTNM 135.4K
  • LOCO 161.5K
  • Earning Date
  • CTNM 02-16-2025
  • LOCO 03-06-2025
  • Dividend Yield
  • CTNM N/A
  • LOCO N/A
  • EPS Growth
  • CTNM N/A
  • LOCO 0.40
  • EPS
  • CTNM N/A
  • LOCO 0.78
  • Revenue
  • CTNM N/A
  • LOCO $470,971,000.00
  • Revenue This Year
  • CTNM N/A
  • LOCO $2.72
  • Revenue Next Year
  • CTNM N/A
  • LOCO $3.75
  • P/E Ratio
  • CTNM N/A
  • LOCO $14.79
  • Revenue Growth
  • CTNM N/A
  • LOCO N/A
  • 52 Week Low
  • CTNM $11.38
  • LOCO $8.17
  • 52 Week High
  • CTNM $22.00
  • LOCO $14.25
  • Technical
  • Relative Strength Index (RSI)
  • CTNM N/A
  • LOCO 45.76
  • Support Level
  • CTNM N/A
  • LOCO $11.16
  • Resistance Level
  • CTNM N/A
  • LOCO $11.86
  • Average True Range (ATR)
  • CTNM 0.00
  • LOCO 0.31
  • MACD
  • CTNM 0.00
  • LOCO 0.05
  • Stochastic Oscillator
  • CTNM 0.00
  • LOCO 67.62

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About LOCO El Pollo Loco Holdings Inc.

El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.

Share on Social Networks: